Molecular mechanisms of selective estrogen receptor modulator (SERM) action

Journal of Pharmacology and Experimental Therapeutics

Volumn 295, Issue 2, 2000, Pages 431-437

  Dutertre, M ^a   Smith, C L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LIGAND; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

CELL TYPE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; GENETIC TRANSCRIPTION; HUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW;

HUMAN; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033775525     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Estrogen activity and novel tissue selectivity of delta 8,9-dehydreestrone sulfate in post-menopausal women
2. Molecular basis of agonism and antagonism in the oestrogen receptor
3. Regulation of hormone induced histene hyperacetylation and gene activation via acetylation of an acetylase
4. Estrogen hits the surface
5. Selective estrogen receptor modulators: Clinical spectrum
6. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha
7. Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: Antiestrogen selectivity and promoter dependence
8. The coregulator exchange in transcriptional functions of nuclear receptors
9. Estrogen receptor β a new dimension in estrogen mechanism of action
10. The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens
11. p300 is a component of an estrogen receptor coactivator complex
12. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
13. Activation of transcription by estrogen receptor alpha and beta is cell type- and promoter-dependent
14. Isoforms of steroid receptor coactivater 1 differ in their ability to potentiate transcription by the oestrogen receptor
15. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones
16. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β
17. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators and corepressors in breast cancer
18. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
19. Binding of antiestrogens exposes an occult antigenic determinant in the human estrogen receptor
20. The molecular pharmacology of SERMs
21. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
22. Nuclear receptor coregulators: Cellular and molecular biology
23. In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators
24. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens
25. Peptide antagonists of the human estrogen receptor
26. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET-SAF-B, a novel inhibiter of ER-mediated transactivation
27. Mechanisms of tamoxifen resistance
28. Differential ligand activation of estrogen receptors ERα and ERβ at AP-1 sites
29. Estrogen receptor modulators each induce distinct conformational changes in ERα and ERβ
30. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
31. Ligand-, cell- and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements
32. The structural basis of estrogen receptor/coactivater recognition and the antagonism of this interaction by tamoxifen
33. Cross-talk between peptide growth factor and estrogen receptor signaling pathways
34. Coactivater and coreprossor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
35. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-α or estrogen receptor-β
36. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
37. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
38. Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta
39. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors
40. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
41. Estrogen receptor activation function 1 works by binding p160 coactivator proteins
42. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone